Overcoming compound interference in fluorescence polarization-based kinase assays using far-red tracers

Assay and Drug Development Technologies

Volumn 2, Issue 2, 2004, Pages 193-203

  Vedvik, Kevin L ^a   Eliason, Hildegard C ^a   Hoffman, Randy L ^a   Gibson, Jasmin R ^a   Kupcho, Kevin R ^a   Somberg, Richard L ^a   Vogel, Kurt W ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 1 (5 ISOQUINOLINESULFONYL)PIPERAZINE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FLUORESCEIN; FLUORESCENT DYE; HA 100; HYPERICIN; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2 GUANIDINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PEPTIDE LIBRARY; PHOSPHORUS 32; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; REAGENT; TRACER;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; AUTOFLUORESCENCE; CELL DIFFERENTIATION; CELL GROWTH; COST; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAR RED LIGHT; FLUORESCENCE ANALYSIS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; IC 50; INTERMETHOD COMPARISON; LIGHT INTENSITY; LIGHT SCATTERING; MOLECULAR SIZE; PATHOGENESIS; PHOTOCHEMICAL QUENCHING; PRECIPITATION; PROTEIN PHOSPHORYLATION; RADIATION; RADIOACTIVITY; REGULATORY MECHANISM; SCINTILLATION; TREATMENT PLANNING; VALIDATION PROCESS; WAVEFORM;

EID: 2442540933     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/154065804323056530     Document Type: Article

References (20)

1. Hemmilä IA: Applications of Fluorescence in Immunoassays (Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications, Vol. 117). John Wiley and Sons Ltd., Chichester, 1991.
2. Jolley ME: Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol 1981;5:236-240.
3. Checovich WJ, Bolger RE, Burke T: Fluorescence polarization - a new tool for cell and molecular biology. Nature 1995;375:254-256.
4. Burke T, Bolger R, Parker G, Schall R: Kinase activity measurement using fluorescence polarization. Filed Oct. 28, 1997; Patent #: WO9818956A1: Published May 7, 1998.
5. Parker GP, Law TL, Lenoch FJ, Bolger RE: Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J Biomol Screen 2000;5:77-88.
6. Turconi S, Shea K, Ashman S, Fantom K, Earnshaw DL, Bingham RP, Haupts UM, Brown MJ, Pope AJ: Real experiences of uHTS: a prototypic 1536-well fluorescence anisotropy-based uHTS screen and application of well-level quality control procedures. J Biomol Screen 2001;6: 275-290.
7. Jameson DM, Croney JC, Moens PDJ: Fluorescence: basic concepts, practical aspects, and some anecdotes. Methods Enzymol 2003;360:1-43.
8. Banks P, Gosselin M, Prystay L: Impact of a red-shifted dye label for high throughput fluorescence polarization assays of G protein-coupled receptors, J Biomol Screen 2000; 5:329-334.
9. Turek-Etienne TC, Lei M, Terracciano JS, Langsdorf EF, Bryant RW, Hart RF, Horan AC: Use of red-shifted dyes in a fluorescence polarization AKT assay for detection of biological activity in natural product extracts. J Biomol Screen 2004;9:52-61.
10. http://www4.amershambiosciences.com/aptrix/upp00919.nsf/Content/ DrugScr+CyDye+Fluors+introduction%5CDrugScr+CyDye+Fluors+Modalities
11. Pope AJ, Haupts UM, Moore KJ: Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. Drug Discov Today 1999;4:350-362.
12. Harris A, Cox S, Burns D, Norey C: Miniaturization of fluorescence polarization receptor-binding assays using Cy-Dye-labeled ligands. J Biomol Screen 2003;8:410-420.
13. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789.
14. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4: 67-73.
15. Zou X, Calame K: Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem 1999; 274:18141-18144.
16. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
17. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H: Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990;265: 5267-5272.
18. Huang, X: Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 2003;8: 34-38.
19. Snider M: Screening of compound libraries ... consommé or gumbo? J Biomol Screen 1998;3:169-170.
20. Chung TDY: Screen compounds singly: why muck it up? J Biomol Screen 1998;3:171-173.